Lineage Cell Therapeutics (XTAE:LCTX) Interest Expense : ₪0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lineage Cell Therapeutics's interest expense for the three months ended in Mar. 2024 was ₪ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lineage Cell Therapeutics's Operating Income for the three months ended in Mar. 2024 was ₪ -24.59 Mil. Lineage Cell Therapeutics's Interest Expense for the three months ended in Mar. 2024 was ₪ 0.00 Mil. GuruFocus does not calculate Lineage Cell Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lineage Cell Therapeutics Interest Expense Historical Data

The historical data trend for Lineage Cell Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Interest Expense Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Lineage Cell Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

Lineage Cell Therapeutics (XTAE:LCTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lineage Cell Therapeutics's Interest Expense for the three months ended in Mar. 2024 was ₪0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₪-24.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₪7.95 Mil.

Lineage Cell Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Lineage Cell Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Lineage Cell Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.